mseokt
2021-10-11
Hopefully an effective drug for treating Covid.
AstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":828462928,"tweetId":"828462928","gmtCreate":1633937343439,"gmtModify":1633937748581,"author":{"id":3577447162748311,"idStr":"3577447162748311","authorId":3577447162748311,"authorIdStr":"3577447162748311","name":"mseokt","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":13,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Hopefully an effective drug for treating Covid.</p></body></html>","htmlText":"<html><head></head><body><p>Hopefully an effective drug for treating Covid.</p></body></html>","text":"Hopefully an effective drug for treating Covid.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/828462928","repostId":1184886071,"repostType":4,"repost":{"id":"1184886071","kind":"news","pubTimestamp":1633937007,"share":"https://www.laohu8.com/m/news/1184886071?lang=&edition=full","pubTime":"2021-10-11 15:23","market":"us","language":"en","title":"AstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1184886071","media":"Bloomberg","summary":"AstraZeneca Plc’s antibody cocktail was effective at preventing people with mild or moderate Covid-1","content":"<p>AstraZeneca Plc’s antibody cocktail was effective at preventing people with mild or moderate Covid-19 infection from worsening in a study.</p>\n<p>The cocktail halved the risk of developing severe illness or death compared with a placebo in a primary analysis of 822 patients who weren’t hospitalized, Astra said in a statement Monday. The trial took place in countries including the U.K., Brazil, the U.S. and Germany.</p>\n<p>The results are another boon for the product after it was also found to be highly effective at preventing symptomatic Covid in high-risk people. The outcomes are a relief for Astra after an initial trial testing whether the cocktail could prevent symptomatic disease in people explicitly exposed to the virus failed in June. The company said last week it had applied for emergency-use authorization in the U.S.</p>\n<p>Antibody treatments are a key tool in the fight against Covid-19 as they can be used to supplement vaccines for people who haven’t mounted a strong response to the shots or to protect those who couldn’t be immunized. Those who may be eligible for such cocktails include cancer patients or those with weakened immune systems.</p>\n<p>“With continued cases of serious Covid-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations,” said Hugh Montgomery, the principal investigator on the trial and professor of intensive care medicine at University College London.</p>\n<p>In a separate analysis of patients who received treatment within five days of getting symptoms, the cocktail reduced the risk of the disease worsening by 67%. The majority of patients -- 90% -- were from populations at high risk of progression to severe Covid-19, including those with co-morbidities.</p>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Antibody Drug Effective at Treating Mild Covid in Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-11 15:23 GMT+8 <a href=https://www.bloomberg.com/news/articles/2021-10-11/astra-antibody-drug-effective-at-treating-mild-covid-in-trial><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AstraZeneca Plc’s antibody cocktail was effective at preventing people with mild or moderate Covid-19 infection from worsening in a study.\nThe cocktail halved the risk of developing severe illness or ...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2021-10-11/astra-antibody-drug-effective-at-treating-mild-covid-in-trial\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN":"阿斯利康","AZN.UK":"阿斯利康制药"},"source_url":"https://www.bloomberg.com/news/articles/2021-10-11/astra-antibody-drug-effective-at-treating-mild-covid-in-trial","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1184886071","content_text":"AstraZeneca Plc’s antibody cocktail was effective at preventing people with mild or moderate Covid-19 infection from worsening in a study.\nThe cocktail halved the risk of developing severe illness or death compared with a placebo in a primary analysis of 822 patients who weren’t hospitalized, Astra said in a statement Monday. The trial took place in countries including the U.K., Brazil, the U.S. and Germany.\nThe results are another boon for the product after it was also found to be highly effective at preventing symptomatic Covid in high-risk people. The outcomes are a relief for Astra after an initial trial testing whether the cocktail could prevent symptomatic disease in people explicitly exposed to the virus failed in June. The company said last week it had applied for emergency-use authorization in the U.S.\nAntibody treatments are a key tool in the fight against Covid-19 as they can be used to supplement vaccines for people who haven’t mounted a strong response to the shots or to protect those who couldn’t be immunized. Those who may be eligible for such cocktails include cancer patients or those with weakened immune systems.\n“With continued cases of serious Covid-19 infections across the globe, there is a significant need for new therapies like AZD7442 that can be used to protect vulnerable populations,” said Hugh Montgomery, the principal investigator on the trial and professor of intensive care medicine at University College London.\nIn a separate analysis of patients who received treatment within five days of getting symptoms, the cocktail reduced the risk of the disease worsening by 67%. The majority of patients -- 90% -- were from populations at high risk of progression to severe Covid-19, including those with co-morbidities.","news_type":1},"isVote":1,"tweetType":1,"viewCount":340,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":41,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/828462928"}
精彩评论